Eli Lilly, Sonofi and Nova Nordisk were the only game in town. These new synthetic insulents were the hottest products that they had developed. And we suddenly started to see prices skyrocket. I believe from 1999 to 2019, the price of some insulents increased by 1000%.
Insulin was the poster child of overpriced life saving drugs, but a manufacturer finally capped the cost at $35. Vox’s Dylan Scott explains how pharmaceutical companies for decades managed to overprice drugs Americans desperately needed.
This episode was produced by Haleema Shah, edited by Amina Al-Sadi, fact-checked by Laura Bullard and Matt Collette, engineered by Patrick Boyd, and hosted by Sean Rameswaram.
Transcript at vox.com/todayexplained
Support Today, Explained by making a financial contribution to Vox! bit.ly/givepodcasts
Learn more about your ad choices. Visit podcastchoices.com/adchoices